Finch To Wind Down, Seek Value For Pipeline Assets And IP

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Following two workforce cuts in 2022, Finch said it will cut its staff by 95%, halting a Phase III study of lead recurrent C. diff candidate CP101 and seeking to maximize shareholder value.

Closing shop
Finch Therapeutics is closing shop after recent setbacks • Source: Shutterstock

Finch Therapeutics Group, Inc. battled to keep its microbiome-focused programs going through two workforce reductions in 2022, but now it appears to be ceding the fight. On 24 January, the Somerville, MA-based firm said it will reduce its headcount by roughly 95%, with the affected positions ending in February, and discontinue a Phase III trial of lead candidate CP101 in recurrent Clostridium difficile infections.

Finch said an assessment by its management team and board of directors determined that the company’s best route forward for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.